BioSpace News Archive

Friday, the Supreme Court granted the FDA’s application for a stay, effectively maintaining access to the abortion pill mifepristone as its case goes through the appeals process.

Eplontersen halted ATTRv-PN disease progression and improved quality of life through 66 weeks. The drug has a PDUFA date of Dec. 22, 2023.

To give the FDA more time to evaluate updates to quizartinib’s proposed REMS program, the regulator is pushing the target action date to July 24.

Amphastar Pharmaceuticals, Inc. announced that the Company will provide a Business update and hold a Conference call , Monday, April 24, 2023, at 6:00 am Pacific Time.

Sensorion a pioneering clinical-stage biotechnology company which specializes in gene therapies in the ear, is pleased to announce it will host a symposium at the 3rd ISIET’s International Symposium on Inner Ear Therapeutics, an event sponsored by Sensorion, taking place on April 28-30, 2023, in Marrakech, Morocco.

Net sales amounted to SEK 140.6 million, corresponding to an increase of 52 percent in SEK and 39 percent adjusted for currency effects.

Ipsen, a global specialty-driven biopharmaceutical company, announced the appointment of Sandra Silvestri, M.D., Ph.D., as EVP, Chief Medical Officer and Head of Global Medical Affairs, Patient Safety and Patient Affairs, effective 5 May 2023.

Samsung Biologics, the world’s leading contract development and manufacturing organization, announced financial results for the first quarter of fiscal year 2023.

BioNxt Solutions Inc. is pleased to announce that it has signed and received payment for a development and manufacturing contract with an international pharmaceutical company.

Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH) today announced that the company will release its first quarter results before the market open on Thursday, May 11, 2023, to be followed by a conference call at 10:00 a.m. (Eastern Time) on the same day.